Although tumor mutational burden (TMB), microsatellite status, and programmed cell death-ligand 1 (PD-L1) expression have been used to predict the effect of immunotherapy (10, 11), the efficiency was limited in PAAD. The gene discussed is CD274; the disease is neoplasm.